Health news and discussion on TalkFuse.
Alzheimer’s brain decline slashed in half by ‘thrilling’ new twice-a-year drug: trial
In a Phase 2 trial, people given low-dose diranersen had 54% less decline in memory and thinking over nearly two years. The experimental drug also reduced aggregated tau, a protein associated with Alzheimer’s-related brain cell damage, raising hopes that it could slow disease progression.
Diranersen is given by injection twice a year and uses gene-silencing technology to reduce the RNA messages that prompt brain cells to produce tau. Researchers said treatment was generally well tolerated, though side effects included lumbar-puncture pain, headaches and confusion, especially at higher doses. A larger Phase 3 trial is needed to confirm the results, and recruitment in the UK is expected to begin in spring.
In short
- Low-dose diranersen was linked to 54% less cognitive decline over nearly two years.
- The trial also found a reduction in aggregated tau.
- Phase 3 testing is needed to confirm the findings.